CA2717511A1 - Modulation of enzymatic structure, activity, and/or expression level - Google Patents

Modulation of enzymatic structure, activity, and/or expression level Download PDF

Info

Publication number
CA2717511A1
CA2717511A1 CA2717511A CA2717511A CA2717511A1 CA 2717511 A1 CA2717511 A1 CA 2717511A1 CA 2717511 A CA2717511 A CA 2717511A CA 2717511 A CA2717511 A CA 2717511A CA 2717511 A1 CA2717511 A1 CA 2717511A1
Authority
CA
Canada
Prior art keywords
modulator
activity
complex
cells
pdh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717511A
Other languages
English (en)
French (fr)
Inventor
Robert Shorr
Robert Rodriguez
Rajinder Bhasin
Paul Bingham
Lakmal W. Boteju
Zuzana Zachar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2717511A1 publication Critical patent/CA2717511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2717511A 2008-03-04 2008-03-04 Modulation of enzymatic structure, activity, and/or expression level Abandoned CA2717511A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/002853 WO2009110859A1 (en) 2008-03-04 2008-03-04 Modulation of enzymatic structure, activity, and/or expression level

Publications (1)

Publication Number Publication Date
CA2717511A1 true CA2717511A1 (en) 2009-09-11

Family

ID=41056265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717511A Abandoned CA2717511A1 (en) 2008-03-04 2008-03-04 Modulation of enzymatic structure, activity, and/or expression level

Country Status (10)

Country Link
EP (1) EP2260019A4 (zh)
JP (1) JP2011513395A (zh)
KR (1) KR20110004846A (zh)
CN (1) CN102089276A (zh)
AU (1) AU2008352076A1 (zh)
BR (1) BRPI0821176A2 (zh)
CA (1) CA2717511A1 (zh)
IL (1) IL207943A0 (zh)
MX (1) MX2010009673A (zh)
WO (1) WO2009110859A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
WO2009123597A1 (en) * 2008-04-04 2009-10-08 Robert Shorr Pharmaceutical composition
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2819175T3 (es) 2014-06-19 2021-04-15 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
TW202038930A (zh) * 2018-12-20 2020-11-01 美商拉斐爾製藥公司 使用6,8-雙-苄硫基-辛酸之口服療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
MXPA01004152A (es) * 1998-10-26 2002-06-04 Univ New York State Res Found Derivados de acido lipoico y su uso en el tratamiento de enfermedades.
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US20020071234A1 (en) * 2000-10-25 2002-06-13 George Alexanian Battery powered programmable remote switch controller
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
AU2008242827B2 (en) * 2007-04-18 2014-06-05 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체

Also Published As

Publication number Publication date
MX2010009673A (es) 2011-03-15
AU2008352076A1 (en) 2009-09-11
EP2260019A1 (en) 2010-12-15
CN102089276A (zh) 2011-06-08
IL207943A0 (en) 2010-12-30
JP2011513395A (ja) 2011-04-28
EP2260019A4 (en) 2011-08-03
KR20110004846A (ko) 2011-01-14
WO2009110859A1 (en) 2009-09-11
BRPI0821176A2 (pt) 2015-10-06

Similar Documents

Publication Publication Date Title
Hashemi et al. Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells
Gan et al. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity
CA2720396A1 (en) Pharmaceutical composition
CA2638735A1 (en) Methods to identify inhibitors of the unfolded protein response
An et al. Synthesis and biological evaluation of selenium-containing 4-anilinoquinazoline derivatives as novel antimitotic agents
WO2009025781A1 (en) Activators of pyruvate kinase m2 and methods of treating disease
JP2014512337A (ja) スチルベン類似体およびがんを処置する方法
Sandoval-Acuña et al. Destabilization of mitochondrial functions as a target against breast cancer progression: Role of TPP+-linked-polyhydroxybenzoates
Lee et al. 15-Keto prostaglandin E2 suppresses STAT3 signaling and inhibits breast cancer cell growth and progression
CA2717511A1 (en) Modulation of enzymatic structure, activity, and/or expression level
Liu et al. Tumor killing by a dietary curcumin mono-carbonyl analog that works as a selective ROS generator via TrxR inhibition
Li et al. Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
US20170218003A1 (en) Pharmaceutical compounds
US10526357B2 (en) Pharmaceutical compounds
AU2013364387B2 (en) Pharmaceutical compounds
CA2829654C (en) Small molecules that replace or agonize p53 function
Oh et al. Selective targeting of cancer cells using a hydrogen peroxide-activated Hsp90 inhibitor
Lee et al. Concurrent induction of apoptosis and necroptosis in apigenin‑treated malignant mesothelioma cells: Reversal of Warburg effect through Akt inhibition and p53 upregulation
WO2010110887A1 (en) Fatty acids
JP2010527328A (ja) 金属トリアングロ化合物およびその使用方法
US11352382B2 (en) Mito-lonidamine, compositions and methods of use
Szlachcikowska et al. Role of Ciminalum-4-thiazolidinone Hybrids in Molecular NF-κB Dependent Pathways

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130304

FZDE Discontinued

Effective date: 20150929